On Invalid Date, Denali Therapeutics (NASDAQ: DNLI) reported Q4 2023 earnings per share (EPS) of -$0.87, up 16% year over year. Total Denali Therapeutics earnings for the quarter were -$119.47 million. In the same quarter last year, Denali Therapeutics's earnings per share (EPS) was -$0.75.
As of Q2 2024, Denali Therapeutics's earnings has grown year over year. Denali Therapeutics's earnings in the past year totalled -$145.22 million.
What is DNLI's earnings date?
Denali Therapeutics's earnings date is Invalid Date. Add DNLI to your watchlist to be reminded of DNLI's next earnings announcement.
What was DNLI's revenue last quarter?
On Invalid Date, Denali Therapeutics (NASDAQ: DNLI) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Denali Therapeutics's revenue was $10.28 million.
What was DNLI's revenue growth in the past year?
As of Q2 2024, Denali Therapeutics's revenue has grown 204.74% year over year. This is 62.47 percentage points higher than the US Biotechnology industry revenue growth rate of 142.27%. Denali Therapeutics's revenue in the past year totalled $330.53 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.